Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies

Mass SARS-Cov-2 vaccination campaign represents the only strategy to defeat the global pandemic we are facing. Immunocompromised patients represent a vulnerable population at high risk of developing severe COVID-19 and thus should be prioritized in the vaccination programs and in the study of the va...

Descripción completa

Detalles Bibliográficos
Autores principales: Amodio, Donato, Ruggiero, Alessandra, Sgrulletti, Mayla, Pighi, Chiara, Cotugno, Nicola, Medri, Chiara, Morrocchi, Elena, Colagrossi, Luna, Russo, Cristina, Zaffina, Salvatore, Di Matteo, Gigliola, Cifaldi, Cristina, Di Cesare, Silvia, Rivalta, Beatrice, Pacillo, Lucia, Santilli, Veronica, Giancotta, Carmela, Manno, Emma Concetta, Ciofi Degli Atti, Marta, Raponi, Massimiliano, Rossi, Paolo, Finocchi, Andrea, Cancrini, Caterina, Perno, Carlo Federico, Moschese, Viviana, Palma, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521226/
https://www.ncbi.nlm.nih.gov/pubmed/34671350
http://dx.doi.org/10.3389/fimmu.2021.727850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521226/
https://www.ncbi.nlm.nih.gov/pubmed/34671350
http://dx.doi.org/10.3389/fimmu.2021.727850

Ejemplares similares